drugset / Trial / NCT03130517
Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease
RandomizedCrossoverOpen-labelTreatment
Summary
hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born
Timeline
- Start
- 2017-07-01
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 0.5 g/kg | Intravenous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 1 g/kg | Intravenous |